Aman's Global Market Intelligence

1 · Executive dashboard

Selective risk-on

Regime call: Friday's record S&P close, 14.90 VIX, lower post-jobs yields, broadly higher Asia and slightly positive S&P/Nasdaq futures support risk-on. Constraint: oil is firm as Hormuz shipping remains restricted, CPI is Wednesday, and speculative themes have already rebounded sharply. Participate conditionally; do not equate a calm index future with low underlying risk.

S&P 5007,757.64+0.62% Fri

Nasdaq Composite26,690.62+1.30% Fri

Dow Jones54,036.93+0.28% Fri

Russell 20003,034.49+1.10% Fri

VIX · official14.90−1.65% Fri

U.S. 2Y4.19%Official Fri close

U.S. 10Y4.66%+1 bp overnight

DXY99.69Overnight proxy

WTI$78.56+0.5% overnight

Gold spot$4,333Holding weekly surge

Market / instrument	Latest	Move	Session / interpretation
S&P 500 future	Indicative	+0.1%	Reuters near 08:00 CEST; almost flat
Nasdaq future	Indicative	+0.3%	Modest tech bias
Nikkei 225	66,845	+1.89%	Near 08:15 CEST; strong follow-through
Hang Seng	25,863	+0.76%	Live, not final close
Shanghai Composite	3,957	+0.43%	Live despite soft China inflation
Kospi	6,301	+0.67%	Live rebound
Euro STOXX 50 future	—	Flat	Pre-open Reuters indication
DAX future	—	Flat	Pre-open Reuters indication
FTSE future	—	−0.4%	Pre-open laggard

1 · Oil blocks a clean Goldilocks trade

Confirmed: Reuters reported Hormuz shipping remained a trickle; Brent +0.6% to $84.04 and WTI +0.5% to $78.56. Inference: persistent oil strength can keep inflation-tail risk alive even after weak payrolls.

2 · Asia validates Friday—for now

Nikkei, Kospi and the broader regional index rose after Wall Street records. China inflation undershot forecasts and Chinese blue chips lagged in Reuters' snapshot, showing the risk-on signal is not uniform.

3 · CPI is the gate, not Monday

Reuters cited roughly 45% odds of a September Fed hike, down from 67% a week earlier. Wednesday CPI can reverse that relief. No major U.S. economic release is scheduled Monday.

2 · Market-moving analysis

Confirmed facts vs. inference

Confirmed macro, rates & liquidity

July payrolls contracted by 23,000; unemployment was 4.1%. Friday's rate rally left official Treasury yields at 4.19% (2Y) and 4.65% (10Y).
The live 10Y was about 4.662% Monday as markets prepared for $125B of Treasury issuance this week.
Reuters' economist reference for Wednesday CPI was +0.1% headline and +0.2% core m/m; CNBC/FactSet cited 3.4% y/y headline. These are expectations, not outcomes.
China July consumer and producer inflation undershot forecasts, reinforcing domestic-demand softness. BOJ July opinions flagged inflation risk and possible faster tightening.

Confirmed earnings / inference

With almost 90% of S&P results in, BofA data cited by Reuters showed ex-special-gain EPS growth of 30% y/y and a 76% beat rate. AI-related median EPS growth was 28% versus 12% elsewhere.
Inference: earnings breadth supports the index, but consensus expects AI growth to decelerate next quarter; current multiples still require continued delivery.
CoreWeave, Cisco and Applied Materials form this week's AI stack test: financed compute, networking orders, and equipment/advanced-packaging demand.
A reported Sony–TSMC ¥1T image-sensor plant is strategically relevant to robotics, but Bloomberg relied on an unnamed source and said neither company immediately commented; treat it as reported talks, not a finalized investment.

Geopolitics High

Iran said an Oman shipping-lane arrangement was in final stages but tied reopening to additional U.S. conditions. CNBC reported no direct U.S.–Iran negotiations. A failed deal would transmit through oil, inflation expectations, yields and margins.

Rotation Constructive

Friday's Russell +1.10% and Nasdaq +1.30% showed both breadth and growth leadership. Monday confirmation requires advances not to collapse if the 10Y or crude rises.

Sentiment / positioning Crowded

VIX 14.90 and a record index close indicate confidence. They do not insure against a CPI gap. Low implied volatility plus elevated event risk makes unhedged chasing asymmetric.

3 · Thematic dashboards

AI infrastructure Leader

Performance: prior verified week: SMH +7.80%, NVDA +11.56%; Friday NVDA $223.96.
Catalysts: CRWV Aug. 11; CSCO Aug. 12; AMAT Aug. 13; NVDA Aug. 26.
Read-through: demand quality, utilization, backlog conversion, networking orders, advanced memory/packaging and export commentary matter more than generic “AI” mentions.
Risk: capex financing, customer concentration, power/cooling, export controls, margins and valuation.

Quantum computing Speculative

Leaders: IONQ +21.93% and RGTI +20.00% last week; Friday closes $44.43 and $17.94.
IONQ facts: Q2 revenue $80.1M (+287%), 2026 revenue guide $280–290M; adjusted EBITDA loss $120.3M. Pro-forma post-SkyWater cash/investments stated at $2.0B.
RGTI facts: Q2 revenue $5.1M versus $28.1M operating loss; $541.3M liquidity, no debt. The $100M U.S. funding item is an LOI with contemplated government equity—not cash in hand.
Risk: tiny revenue versus market value, lumpy awards, roadmap claims, dilution and extreme beta. Avoid confusing technical progress with near-term economics.

Peptide / metabolic biotech Demand leader

LLY facts: Q2 revenue $23.0B (+48%); Mounjaro +91%, Zepbound +46%. Full-year revenue guide raised to $85–87B.
Pipeline: Lilly says the retatrutide Phase 3 package supports planned global filings; U.S. filing is planned for Q1 2027, not an approval.
Price pressure: Q2 volume +60% while realized prices fell 13%; growth quality must include access and net price, not prescriptions alone.
Small-cap risk: VKTX remains binary around Phase 3 design, tolerability, discontinuations, cash use and competitive differentiation.

4 · Ranked ideas

Conditional, paper-tracked; no guaranteed direction

#1 NVDA · NVIDIA Bullish / confirmation

Nasdaq · approx. $5.4T mega-cap · AI compute/networking · elevated event and valuation risk

Current session: breakout watch1–4 weeks: applicable after CPI3–12+ months: applicable

Thesis / direction: may extend leadership if yields stay contained and this week's AI-stack results validate demand quality.

Catalysts / evidence: CRWV, CSCO and AMAT read-through; company-confirmed Aug. 26 results; Friday $223.96 near $224.76 high.

Counterargument: +11.56% week embeds enthusiasm; export, customer concentration, power/supply and hyperscaler-return risks remain.

Technical / fundamental: strong relative trend; current evidence supports momentum, not a cheap valuation assertion.

Entry / confirmation: liquid-session hold above $224.76 with positive breadth, or post-CPI base above $220.66 and 10Y below 4.70%.

Invalidation / downside: close below $217, 10Y >4.70%, or weaker AI demand/guidance. Earnings gaps can be large.

Principal risks: CPI, rates, export regulation, competition, concentration and capex digestion.

Confidence

Risk

Opportunity

Confidence: primary catalyst + cross-stack evidence 30, market/technical 25, macro fit 23. Risk: valuation/event 25, macro 20, regulation/concentration 20.

#2 LLY · Eli Lilly Bullish long-term / patience

NYSE · approx. $1.1T mega-cap · peptide/metabolic therapeutics · policy, competition and premium-multiple risk

Current session: no clean edge1–4 weeks: confirmation3–12+ months: disciplined entry

Thesis / direction: verified incretin volume and raised guidance may support long-run compounding, but near-term direction remains volatile after earnings.

Catalyst / evidence: Q2 revenue +48%; Mounjaro +91%, Zepbound +46%; manufacturing and regulatory updates.

Counterargument: realized price −13%, premium valuation, reimbursement, supply, competition and safety can compress expectations.

Context: $1,185.71 Friday close; range $1,161.20–$1,196.80. Profitable mega-cap, but concentrated metabolic narrative.

Entry / confirmation: close above $1,196.80 or multi-session base above $1,161.20; avoid blind averaging.

Invalidation / downside: sustained break below $1,161 with estimate cuts, access deterioration, safety signal or manufacturing shortfall.

Principal risks: pricing/policy, competitors, safety, litigation, manufacturing and pipeline execution.

Confidence

Risk

Opportunity

Confidence: primary financial evidence 35, catalyst visibility 23, operating momentum 22. Risk: valuation 20, policy/price 18, clinical/supply 20.

#3 RGTI · Rigetti Avoid chasing · not a short

Nasdaq · approx. $6B speculative small/mid-cap · quantum · extreme volatility, dilution and squeeze risk

Current session: avoid1–4 weeks: no short edge3–12+ months: milestone watch

Thesis / direction: $5.1M quarterly revenue and $28.1M operating loss do not justify chasing the 20% weekly rebound; price can still rise on policy/momentum.

Catalyst / evidence: Q2 roadmap, deployments and up-to-$100M Commerce LOI; large liquidity extends runway.

Counterargument: no debt, $541.3M liquidity, government interest and technical milestones can sustain a strategic premium.

Context: $17.94 close at $17.95 high on heavy volume; momentum makes shorting especially dangerous.

Confirmation: reconsider long after funded recurring awards and commercial conversion; bearish trade would require failed breakout and close below $16.40.

Invalidation / downside: avoid view weakens on large recurring wins and verified scaling. Long downside is multiple collapse/dilution.

Principal risks: small revenue, technical execution, dilution and squeeze; no borrow terms asserted.

Confidence

Risk

Opportunity

#4 IONQ · IonQ Avoid at price · not a short

NYSE · approx. $16B speculative mid-cap · quantum platform/foundry · high loss, M&A and dilution risk

Current session: avoid volatility1–4 weeks: no edge3–12+ months: conversion watch

Thesis / direction: 287% growth is real, but loss intensity and +21.93% weekly momentum leave weak risk/reward without operating leverage.

Catalyst / evidence: raised $280–290M guide, platform deployment and SkyWater integration; adjusted EBITDA loss $120.3M.

Counterargument: pro-forma $2.0B liquidity, broader product mix and commercial/international revenue can support strategic value.

Context: $44.43 close near $44.62 high; strong momentum and M&A accounting complicate valuation.

Confirmation: require recurring conversion, gross-margin durability and narrowing loss/cash-burn intensity, or a valuation reset.

Invalidation / downside: avoid view changes on verified margin inflection. Downside: integration, dilution and multiple compression.

Principal risks: roadmap, procurement timing, warrants, M&A and squeeze; no borrow terms asserted.

Confidence

Risk

Opportunity

Watchlist · confirmation needed

CRWV · CoreWeave High-risk watch

Nasdaq · large-cap, high leverage/concentration risk · AI cloud

Classification/horizon: watch, no pre-earnings day trade; 1–4 weeks after Aug. 11. Thesis/catalyst: demand and backlog may validate AI compute, but financing quality matters. Evidence/context: $90.67 close, +6.3% Friday; earnings Tuesday. Confirm: utilization, backlog conversion, cash generation and financing. Counter/invalidation/downside: concentration, debt/capex or weak unit economics; reassess only on durable free-cash path. Risks: leverage, customers, GPU supply, pricing. C/R/O: 58/87/62.

CSCO · Cisco Watch

Nasdaq · mega-cap · AI/data-center networking · moderate event risk

Classification/horizon: watch; 1–4 weeks/investment after Aug. 12. Thesis/catalyst: AI networking orders may broaden growth. Evidence/context: $121.43 Friday; earnings Wednesday. Confirm: orders, margins and guide—not AI wording. Counter/invalidation/downside: enterprise weakness, competition or guide miss; bullish case fails if order growth lacks margin conversion. Risks: cycle, competition, integration. C/R/O: 68/64/66.

AMAT · Applied Materials Watch

Nasdaq · mega-cap · semiconductor equipment/AI enabler · cycle/export risk

Classification/horizon: watch; 1–4 weeks after Aug. 13 call. Thesis/catalyst: advanced-node, memory and packaging spend may sustain orders. Evidence/context: $539.14 Friday; company-confirmed 16:30 ET call. Confirm: guide/orders and high-volume hold. Counter/invalidation/downside: China/export limits or capex rollover; fail on weak forward orders. Risks: valuation, cycle, regulation. C/R/O: 70/69/67.

VKTX · Viking Therapeutics Speculative biotech

Nasdaq · approx. $4B mid-cap biotech · peptide/metabolic · binary/dilution risk

Classification/horizon: high-risk speculative watch; 3–12 months. Thesis/catalyst: VK2735 could offer competitive injectable/oral profiles; Phase 3 execution is the gate. Evidence/context: $34.26 Friday; prior oral tolerability concerns remain relevant. Confirm: registered Phase 3 design, endpoints, powering, discontinuations and runway. Counter/invalidation/downside: inferior efficacy/tolerability or financing; binary drawdown can be severe. Risks: clinical, regulatory, competition, cash/dilution. C/R/O: 55/89/59.

QBTS · D-Wave Quantum Speculative watch

NYSE · approx. $7B speculative mid-cap · quantum annealing/gate model · extreme valuation risk

Classification/horizon: watch-confirmation-needed; no day-trade edge, 3–12 month milestone view. Thesis/catalyst: bookings and annealing deployments may convert earlier than gate-model peers. Evidence/context: $20.76 Friday; primary Q2 page was blocked in this run, so no unverified Q2 metric is promoted. Confirm: SEC-filed revenue, bookings, cash use and recurring conversion. Counter/invalidation/downside: lumpy tiny revenue and multiple compression; thesis fails on bookings non-conversion. Risks: cash burn, technology, dilution, squeeze. C/R/O: 48/93/50.

5 · Changes since Aug. 9

Regime retained: risk-on/event-sensitive. Futures reopened almost flat-to-positive and Asia broadly advanced, validating—but not strengthening—the Sunday call.
New risk: oil firmed as Hormuz shipping remained constrained. Geopolitical risk is now price-confirmed rather than only a weekend headline.
NVDA: remains #1; Risk 64→65 and Opportunity 75→74 because the tape is closer to a CPI/earnings event cluster without a new company datapoint.
LLY: Confidence 79→80 after direct reconciliation of Q2 volume, realized-price and guidance details; classification unchanged.
Quantum: no upgrade despite positive Asia. RGTI/IONQ remain avoid-chasing, not shorts. QBTS added as watch-only because Q2 primary retrieval was blocked and evidence quality is insufficient for an action call.
No completed call audit today: no U.S. cash session has occurred since the prior report. Initial two-week paper tracking continues.

6 · Important 7–30 day catalysts

Times ET; verify near event

Aug. 10 · Monday — No major U.S. macro release

Watch oil/Hormuz, breadth, yields and whether Asian strength carries into Europe/U.S.

Aug. 11 · 08:15 / 10:00 — ADP weekly employment / existing-home sales

Secondary labor and housing signals; CoreWeave and Super Micro earnings after the close.

Aug. 12 · 08:30 — July CPI

Primary cross-asset gate. Reuters expectation reference: +0.1% headline, +0.2% core m/m; confirm consensus immediately before release.

Aug. 12 · after close — Cisco FY26 results

AI networking orders, enterprise demand, margins and guidance.

Aug. 13 · 08:30 — July PPI + jobless claims

Pipeline inflation and PCE read-through.

Aug. 13 · 16:30 — Applied Materials Q3 call

Company-confirmed. Foundry/logic, memory, packaging and export commentary.

Aug. 14 · 08:30 / 10:00 — Retail sales / Michigan sentiment

Consumption and inflation-expectations check after weak payrolls.

Aug. 19 · 14:00 — FOMC minutes

Policy-division detail from the July meeting; timing follows the Fed calendar.

Aug. 26 · 14:00 PT — NVIDIA Q2 FY27 results

Company-confirmed. Compute/networking demand, supply, margins, export controls and next-quarter guide.

Next 30 days — Biotech verification queue

No new company-confirmed PDUFA or pivotal VKTX event was found for the next 30 days in this run. Do not manufacture a binary date; monitor company IR, FDA calendar and ClinicalTrials.gov updates.

7 · Bottom line

Current-session / day trade

NVDA breakout only on confirmation. Require a liquid hold above $224.76 with positive breadth and stable yields. Otherwise, no compelling day-trade edge before CPI.

1–4 week swing

NVDA after CPI and AI-stack read-through. Best evidence is relative strength plus near-term demand tests. Invalidate below $217 or on 10Y >4.70%/weak guidance.

3–12+ month investment

LLY on disciplined entries. Verified volume and guidance lead the focused universe. Change view on estimate/access deterioration, safety, manufacturing or competitive failure.

Biggest risk: stagflation—hot CPI plus constrained oil flows after weak payrolls—would challenge both earnings confidence and long-duration multiples. Regime downgrade: oil breaks higher, 10Y closes above 4.70%, CPI exceeds expectations, or index highs occur with collapsing breadth. Upgrade: benign CPI, easing oil/yields and broad earnings confirmation.

Sources & data quality

Data-quality panel

U.S. cash prices are Friday Aug. 7 closes. Asian levels and Yahoo commodity/futures proxies were retrieved near 08:15 CEST; Reuters' market article provided cross-checked percentage indications. Asian values were still live and can differ from final closes.
European cash markets had not opened. Reuters supplied pre-open futures direction; exact contracts were not available consistently, so no false precision is shown.
Official Treasury data directly confirm Friday 2Y 4.19% and 10Y 4.65%; Reuters reported Monday 10Y near 4.662%. Cboe directly confirms VIX 14.90.
Markets Insider's earlier futures snapshot and CNBC's earlier Sunday snapshot differed from Reuters' later update; the later Reuters values are used. This illustrates timestamp risk, not necessarily bad data.
Primary company sources succeeded for IonQ, Rigetti, Lilly, NVIDIA and Applied Materials. D-Wave IR was blocked/private-address classified; its Q2 metrics were therefore not used. CoreWeave's guessed IR URL returned 404; Reuters/CNBC independently confirmed the earnings week, but exact call time should be checked with IR.
Several web-search requests hit a per-minute rate limit; accessible Reuters, CNBC, Yahoo, Treasury, Cboe and primary IR alternatives succeeded, so core dashboard data are available. No claim rests solely on a blocked source.
Market caps are approximate and especially unstable for speculative names. Confidence scores measure evidence quality, not probability of gain.